cotarnine: structure
ID Source | ID |
---|---|
PubMed CID | 6715 |
CHEMBL ID | 4745550 |
CHEBI ID | 166583 |
SCHEMBL ID | 679713 |
MeSH ID | M0045839 |
Synonym |
---|
4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
82-54-2 |
CHEBI:166583 |
nsc-121978 |
59760-32-6 |
nsc121978 |
cotarnine |
1,3-dioxolo(4,5-g)isoquinolin-5-ol, 5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
cotarnin |
einecs 201-429-8 |
5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-ol |
brn 0022879 |
AKOS005605723 |
STK693623 |
4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
79v56tdi6g , |
4-27-00-06448 (beilstein handbook reference) |
unii-79v56tdi6g |
FT-0624071 |
(+/-)-cotarnine |
cotarnine [mi] |
cotarnine, (+/-)- |
cotarnine [who-dd] |
SCHEMBL679713 |
5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-ol |
PAPMYQLKLNRZIR-UHFFFAOYSA-N |
4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-ol # |
4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxol[4,5-g]isoquinolin-5-ol |
1,3-dioxolo[4,5-g]isoquinolin-5-ol,5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
DTXSID80274484 |
sr-01000884006 |
SR-01000884006-1 |
mfcd00190616 |
99781-53-0 |
4-methoxy-6-methyl-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
NS-03227 |
Q27266783 |
4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
XC160978 |
4-methoxy-6-methyl-5,6,7,8-tetrahydro-2h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
DTXSID40871559 |
CHEMBL4745550 |
EN300-302336 |
Excerpt | Reference | Relevance |
---|---|---|
"Noscapine, a phthalideisoquinoline alkaloid derived from opium, has been used as an oral anti-tussive agent and has shown very few toxic effects in animals or humans." | ( Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Archer, DR; Grossniklaus, HE; Joshi, HC; Kapp, JA; Ke, Y; Ye, K, 2000) | 0.31 |
Class | Description |
---|---|
isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.11) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |